Anzeige
Mehr »
Login
Dienstag, 21.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Aktienchance des Jahres! Ihre Chance auf explosive Gewinne!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 854607 | ISIN: JP3814000000 | Ticker-Symbol: FJI
Tradegate
20.01.25
13:18 Uhr
20,240 Euro
-0,070
-0,34 %
Branche
Konsumgüter
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
FUJIFILM HOLDINGS CORPORATION Chart 1 Jahr
5-Tage-Chart
FUJIFILM HOLDINGS CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
20,15020,50020.01.
20,10020,51020.01.
GlobeNewswire (Europe)
840 Leser
Artikel bewerten:
(2)

FUJIFILM Europe GmbH: New DeepInsight 'the next stage' by FUJIFILM

Finanznachrichten News

Explore the depths of ultrasound for early diagnosis.

RATINGEN, Germany, Nov. 09, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Europe is proud to launch the next stage of DeepInsight, an innovative ultrasound technology that supports early and accurate diagnosis, treatment, and follow-up management for imaging professionals.

Our AI-powered ultrasound imaging solution is designed for clinicians and radiology specialists who need access to detailed imaging information and the ability to deliver an enhanced scanning experience for patients.

Rich in contrast and spatial resolution, our innovative ultrasound imaging system focuses on improving diagnostic accuracy, together with scanning efficiencies that deliver value to healthcare professionals and patients.

"Pursuing the development of user-friendly solutions, FUJIFILM Healthcare Europe offers the next stage in diagnostic technology with our latest update of DeepInsight.

Whatever the clinical challenge, our innovative AI-based solution, with new beamforming technology, has the flexibility to meet challenging expectations throughout the patient journey, from diagnosis to treatment support and follow-up management, for the benefit of the patient".

- Anne-Laure Jet, European Ultrasound Product Manager

IMPROVING DIAGNOSTIC ACCURACY

The newly released update for the DeepInsight ultrasound solution offers enhanced image quality by emphasising tissue structures with a rich gradation. Our sophisticated beamforming technology allows improved visibility of complex tissue structures, supporting clinicians with more in-depth information and improved clinical decision-making in the diagnosis-to-treatment process.

SUPPORTING LESS-TIME CONSUMING EXAMINATIONS

With an optimised scanning experience and greater imaging accuracy, the technology featured in this new release supports imaging specialists in delivering less time-consuming detection and examination services for patients, contributing to early diagnosis and improved patient outcomes. The new easy-to-use features simplify the operation of ultrasound devices, allowing a greater focus on the patient experience during procedures.

INNOVATIVE DEEP LEARNING FOR PATIENT WELLBEING

Anne-Laure Jet, European Ultrasound Product Manager, said, "Our new AI-based system* has been developed using deep learning, to exceed user requirements and contribute to healthcare development and patient wellbeing."

With technology that improves image quality, the new version of FUJIFILM's ultrasound DeepInsight solution provides clearer imaging results whilst ensuring user and patient wellbeing during procedures, to assist radiology departments in delivering a better patient experience.

* The technology was developed using machine learning AI technology. The performance and accuracy of the system does not automatically change after implementation.

CMUT PROBE COMPATIBILITY (Arietta® 750DeepInsight and 850DeepInsight)

The newly enhanced DeepInsight has been designed with compatibility in mind. It supports healthcare professionals in using our patented, high-powered probe, featuring innovative CMUT (Capacitive Micromachined Ultrasound Transducers) Silicon Wafer Technology. Including a wider frequency bandwidth of 22-2 MHz, it enables an ideal acoustic match to the human body, increasing the quality and accuracy of imaging results across a wide range of ultrasound procedures.

"We are excited to introduce our latest ultrasound technology, which delivers a deeper imaging clarity and precision, empowering healthcare professionals to support more accurate diagnoses and enhance patient care".

- Maria Paola Aquilone, European Marketing Manager Ultrasound Systems

Now Available!
New DeepInsight 'the next stage' will be available, for Arietta® 750 and 850 DeepInsight, in Europe from 9th November 2024.

Join Us In Naples
Come and see DeepInsight 'the next stage' LIVE at Booth 18-19 at EUROSON Congress 2024. From 9-11 November, Naples.

Fujifilm, Proudly by Your Side
Recently celebrating 90 years as a global innovator in healthcare and imaging, Fujifilm's innovative medical-technology solutions are designed to improve patient accessibility to healthcare services, with early diagnosis and medical treatments that deliver a continued positive impact on our society. With our knowledge, passion and inspiration, we empower Healthcare Professionals to make the biggest difference in their daily work byimprovingthe quality of life for patients. Together, we are enriching lives and giving the world more smiles!

Learn More

Visit the Fujifilm Healthcare Europe website: https://global.fujifilm.com/en/all-regions/eu

Contact Us
Want to learn more about this product or have a question for our team?

Contact us here:

Maria Paola Aquilone (European Marketing Manager Ultrasound systems)
maria.paola.aquilone@fujifilm.com

Anne Laure Jet

Proudly by your side,
Your Fujifilm Healthcare Europe Team

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/232bd753-18ac-4524-a2cf-79f097bc703c


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.